Terms: = Skin cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
335 results:
1. Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis.
Sahraoui G; Rahoui N; Driss M; Mrad K
Int Rev Cell Mol Biol; 2024; 384():47-61. PubMed ID: 38637099
[TBL] [Abstract] [Full Text] [Related]
2. Combined therapy of dabrafenib and an anti-her2 antibody-drug conjugate for advanced BRAF-mutant melanoma.
Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
[TBL] [Abstract] [Full Text] [Related]
3. Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer.
Zhang J; Zhang J; Niu X; Zhou Y; Guo Y; Wang Y; Shou F
Sci Rep; 2024 Mar; 14(1):6003. PubMed ID: 38472493
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and Characterization of a TP53-Mutated Eyelid Sebaceous Carcinoma Cell Line.
Gu X; Huang Z; Chen J; Luo Y; Ge S; Jia R; Song X; Chai P; Xu S; Fan X
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):16. PubMed ID: 38095907
[TBL] [Abstract] [Full Text] [Related]
5. Effect of Neoadjuvant Concurrent Chemoradiation on Operability and Survival in Locally Advanced Inoperable Breast cancer.
Iyer P; Krishnamurthy A; Velusamy S; Sundersingh S; Rajaram S; Balasubramanian A; Radhakrishnan V
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):163-171. PubMed ID: 38036271
[TBL] [Abstract] [Full Text] [Related]
6. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract] [Full Text] [Related]
7. A case report and literature review on a rare subtype of triple-negative breast cancer in children.
Shi L; Zhang Y; Wu J; Li J; Zhu J; Xu Y; Li N; Li Q; Zhang W
BMC Pediatr; 2023 Sep; 23(1):494. PubMed ID: 37773118
[TBL] [Abstract] [Full Text] [Related]
8. Use of Drugs in Clinical Practice and the Associated Cost of cancer treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
[TBL] [Abstract] [Full Text] [Related]
9. Receptor conversion and survival in breast cancer liver metastases.
Sundén M; Norgren S; Lundqvist R; Andersson A; Sund M; Hemmingsson O
Breast Cancer Res; 2023 Sep; 25(1):105. PubMed ID: 37705026
[TBL] [Abstract] [Full Text] [Related]
10. Brave new world-new and emerging treatments for gastric cancer.
Lynch E; Duffy AG; Kelly RJ
Chin Clin Oncol; 2023 Oct; 12(5):54. PubMed ID: 37691344
[TBL] [Abstract] [Full Text] [Related]
11. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL; Moy RH; Cowzer D; Shah RH; Chou JF; Joshi SS; Ku GY; Maron SB; Desai A; Yang J; Sugarman R; Rao D; Goldberg Z; Charalambous C; Lapshina M; Antoine A; Socolow F; Trivedi N; Capanu M; Gerdes H; Schattner MA; Simmons M; Lacouture ME; Paroder V; Tang LH; Shia J; Ilson DH; Solit DB; Berger MF; Janjigian YY
Lancet Oncol; 2023 Oct; 24(10):1073-1082. PubMed ID: 37666264
[TBL] [Abstract] [Full Text] [Related]
12. Long-term survival in patients with brain metastases-clinical characterization of a rare scenario.
Hügel M; Stöhr J; Kuhnt T; Nägler F; Papsdorf K; Klagges S; Hambsch P; Güresir E; Nicolay NH; Seidel C
Strahlenther Onkol; 2024 Apr; 200(4):335-345. PubMed ID: 37646818
[TBL] [Abstract] [Full Text] [Related]
13. Breast cancer vaccines; A comprehensive and updated review.
Al-Hawary SIS; Saleh EAM; Mamajanov NA; S Gilmanova N; Alsaab HO; Alghamdi A; Ansari SA; Alawady AHR; Alsaalamy AH; Ibrahim AJ
Pathol Res Pract; 2023 Sep; 249():154735. PubMed ID: 37611432
[TBL] [Abstract] [Full Text] [Related]
14. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice.
Sibaud V; Sollena P
Ann Dermatol Venereol; 2023 Sep; 150(3):208-212. PubMed ID: 37586898
[TBL] [Abstract] [Full Text] [Related]
15. ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast cancer CNS Metastasis.
Tew BY; Kalfa AJ; Yang Z; Hurth KM; Simon T; Abnoosian E; Durant ST; Hamerlik P; Salhia B
Clin Cancer Res; 2023 Nov; 29(21):4492-4503. PubMed ID: 37585496
[TBL] [Abstract] [Full Text] [Related]
16. Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report.
Ozawa Y; Fujimiya T; Shimada A; Okazawa A; Kusano J; Yamamoto R; Hyasashi S
Anticancer Drugs; 2024 Jan; 35(1):89-92. PubMed ID: 37578747
[TBL] [Abstract] [Full Text] [Related]
17. Lung cancer with breast metastasis: a case report and review of the literature.
Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
[TBL] [Abstract] [Full Text] [Related]
18. KS-EMPD-1: a novel cell line of primary extramammary Paget's disease.
Ito T; Tanaka Y; Ichiki T; Kaku-Ito Y; Nakahara T
Hum Cell; 2023 Sep; 36(5):1813-1829. PubMed ID: 37432591
[TBL] [Abstract] [Full Text] [Related]
19. The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence.
Zhou D; Li M; Xu F; Zheng Q; Lu Q; Hong R; Wang S
Ann Med; 2023 Dec; 55(1):2232299. PubMed ID: 37431586
[TBL] [Abstract] [Full Text] [Related]
20. Safety and Tolerability of a Novel Anti-her2 Antibody-Drug Conjugate (PF-06804103) in Patients with her2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.
Meric-Bernstam F; Calvo E; Lee KS; Moreno V; Park YH; Rha SY; Chalasani P; Zhong W; Zhou L; Pirie-Shepherd S; Leung ACF; Curigliano G
Mol Cancer Ther; 2023 Oct; 22(10):1191-1203. PubMed ID: 37420274
[TBL] [Abstract] [Full Text] [Related]
[Next]
